Lipids and cardiovascular/metabolic health

Fatty acid regio-specificity of triacylglycerol molecules may affect plasma lipid responses to dietary fats—a randomised controlled cross-over trial

Welma Stonehouse1 · Bianca Benassi-Evans1 · Genevieve James-Martin1 · Mahinda Abeywardena1

Received: 2 January 2019 / Accepted: 28 May 2019
© The Author(s) 2019. This article is published with open access

Abstract

Background/Objectives Hypercholesterolaemic effects of saturated fatty acids (SFA) may be influenced not only by the chain length, but also by their specific location within the triacylglycerol (TAG) molecule. We examined the hypothesis that dietary fats rich in SFA, but containing mostly unsaturated fatty acids in the sn-2 position with most SFA in sn-1 and -3 (palm olein [PO] and cocoa butter [CB]) will have similar serum lipid outcomes to unsaturated olive oil (OO).

Subjects/Methods Thirty-eight participants (20–40 yr, 18.5–≤27.5 kg/m2) completed a 4-week randomised 3 × 3 crossover feeding intervention, preceded by 2-week run-in and separated by 2-week washout periods. Background diet contained 35 percentage of total energy (%E) fat, 18%E protein, 48%E carbohydrates, differing in test fats only (palm olein (PO), CB, OO; 20%E). Total cholesterol (TC)/high density lipoprotein cholesterol (HDL-C) ratio and related variables; TC, HDL-C, low density lipoprotein cholesterol (LDL-C), TAG, apoA1, ApoB, ApoA1 (apolipoprotein A1)/ApoB (apolipoprotein B), lipoprotein (a) (Lp(a)), NEFA, LDL sub-fractions, were assessed pre- and post-intervention. Data were analysed using mixed effects longitudinal models with a P-value < 0.05 considered significant.

Results Changes in plasma fatty acids (P < 0.05) confirmed compliance; C18:1 increased with OO compared to PO and CB; C16:0 decreased with OO and C18:0 increased following CB. No differences were seen for TC/HDL-C (mean [95%CI] change for PO, 0.08[0.00, 0.15] mmol/L; CB, 0.06 [−0.05, 0.16] mmol/L; and OO, −0.01 [−0.15, 0.13] mmol/L; P = 0.53) or any other parameter including LDL sub-fractions. OO decreased IDL-A compared to PO (−2.2 [−4.31, −0.21] mg/dL, P = 0.03).

Conclusion In healthy young participants, plasma lipid responses to PO and CB, enriched in SFA but having primarily unsaturated fatty acid in the sn-2 position of TAG, did not differ from OO.

Introduction

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, accounting for one-third of all global deaths [1]. Reducing saturated fatty acids (SFA) is a key dietary strategy for lowering CVD risk, based primarily on its cholesterol-raising effects; [2] although for many countries the intake of SFA remain higher than recommended intakes [3].

SFA are used in the manufacturing of a number of foods and confectionary products, as they provide desirable and complementary attributes and functions, not equalled by unsaturated fats. For example, SFA are more oxidatively stable and contributes significantly more to the texture, flavour, sensory and mouth feel properties of food compared to unsaturated fats. Furthermore, most SFA can be transformed into margarines and shortenings without the need for hydrogenation. This is an important quality as these fats can replace hydrogenated fats, previously used for this purpose, but no longer recognised as safe [4]. Although SFA containing commodity fats and oils, such as palm and palm stearin, are considered better options in terms of

Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au: ACTRN12616000069459

Supplementary information The online version of this article (https://doi.org/10.1038/s41430-019-0452-7) contains supplementary material, which is available to authorized users.

Welma Stonehouse welma.stonehouse@csiro.au

1 Commonwealth Scientific Industrial Research Organisation, Health and Biosecurity, Adelaide, South Australia, Australia
studies that used various dietary sources of SFA \[6, 7\] potentially resulting in inaccurate conclusions. Cholesterol-olaemic effects may differ depending on the chemical structure of fatty acids within the dietary SFA \[5\]. Evidence from animal studies show that whilst long-chain SFA esterified to sn 1,3 positions are rapidly cleaved by pancreatic and intestinal lipases and released into the intestine, they are not efficiently absorbed due to the formation of insoluble calcium and magnesium salts and are largely excreted in the faeces \[8, 9\]. In contrast, the sn 2 fatty acid (s) are absorbed efficiently as monoglycerides and transported to the liver where they may influence cholesterol homeostasis differently compared to when occupying sn−1,3 positions \[5, 10, 11\]. Limited evidence exists in humans to support the hypothesis that triacylglycerol (TAG) structure might influence lipid metabolism. Original speculation was based on observations that infants fed breast milk, with palmitic acid (PA) predominantly esterified to the sn-2 position (−75%) absorbed fat better compared to formulas based on sn-1,3-palmitate from palm oil \[12\]. Although palm olein (PO) is rich in SFA, the sn-2 position is predominantly occupied by unsaturated fatty acids (~87%, oleic acid and linoleic acid), while in animal fats such as lard, the sn-2 position is mainly SFA (about 87%, PA and stearic acid) \[2\]. Hence, even though PO and lard have similar proportions of SFA (43 and 39%, respectively) and unsaturated fatty acids (57 and 56%, respectively), they differ in their positional distribution within the TAG molecule. Comparisons between lard and PO on plasma cholesterol outcomes have, however, been inconsistent \[13–15\]. Similarly, a limited number of small intervention studies that compared effects of increased PA in the sn-2 position (using interesterification) to fats with PA in sn-1,3, were unable to show differences in cholesterol levels \[10, 16, 17\]. Nevertheless, more recent animal and human studies using interesterified fats have assigned an important role for fatty acid(s) occupying the sn2 position for several metabolic outcomes \[18\].

In the present study, we tested the hypothesis that dietary fats high in SFA, but containing mostly unsaturated fatty acids in the sn-2 position (PO and cocoa butter [CB]) will behave more like an unsaturated fat source (olive oil [OO]) in terms of their effects on lipid profiles, regardless of their total SFA content.

The current study represents the Australian arm of a larger study conducted in several centres, all following the same protocol.

Subjects/methods

The trial (http://www.anzctr.org.au; ACTRN1261600069459) was conducted at CSIRO’s Nutrition and Health Research Clinic, Adelaide, SA, Australia between May and November 2016 according to National Health and Medical Research Council National Statement on Ethical Conduct in Human Research and ethics approval obtained from CSIRO Human Research Ethics Committee (HREC#15/2015). Participants provided written informed consent.

Participants

Healthy adults (20–40 years; body mass index (BMI) 18.5–≤27.5 kg/m²) were recruited. Exclusion criteria were: abnormal liver and kidney function (elevated alanine transaminase (ALT), aspartate transaminase (AST), creatinine), history of chronic disease, pancreatic insufficiency or fat malabsorption conditions, smoking 6 months prior, lipid/blood pressure (BP) lowering medication, BP > 140/90 mmHg, hyperlipidemia (fasting total cholesterol [TC] > 6.2 mmol/L, TAG > 2.0 mmol/L), allergies to intervention foods, pregnancy/breastfeeding, supplements affecting study outcomes, active weight-loss, hormone-based contraceptives < 3 months prior, hypo-/hyperthyroidism.

Study design

A 4-week single-blind, randomised 3 × 3 crossover feeding intervention, preceded by 2-week run-in and separated by 2-week washout periods. Participants were stratified by gender and randomly assigned to one of three allocation sequences generated by an individual independent to study allocations using http://www.randomization.com/. Staff involved in data collection and analysis were blind to allocations. Participants and research dietitians were not fully blinded as appearance and flavour of test fats differed.

Outcome measures were assessed pre- and post-intervention. Blood samples were collected following overnight fast; weight and height were measured and BMI calculated; BP were measured using an automated BP monitor [Philips SureSigns VS3]. Participants were asked to maintain usual exercise patterns and limit intake of medications.

Experimental diets

Participants consumed similar diets differing in test fats only, containing either OO (purchased locally, La Espanola Extra Virgin Olive Oil), PO (IV64) (supplied by Malaysian Palm Oil Board), or CB (Guon Chong Cocoa Manufacturer, Malaysia). Olive oil was chosen as the comparison fat as the fatty acid(s) occupying the sn-2 position of TAGs are...
comparable to that of the two test fats (PO and CB), namely low SFAs but enriched with monounsaturated fatty acids (MUFAs) (Table 1). Furthermore, the polyphenol content of OO was thought unlikely to affect lipid profiles [19]. During the run-in and washout periods, PO (IV72) was used (Table 1) because of its slightly different composition than the test PO (IV64) and to achieve uniformity across different study centres. As the purpose of the run-in/washout fat is to bring study participants to an equilibrium (all participants consuming the same fat) before changing over to a different intervention fat, the type of fat used was considered irrelevant. Experimental diets delivered 30–35 percentage of total energy (%E) as total fat with 20%E derived from test fats (~44 g fat/day for 8400 kJ diet), ~15%E protein and ~50%E carbohydrate. Test fats were provided via two frozen meals (lunch, dinner), biscuits (consumed daily) and cake (consumed on weekends in lieu of one frozen meal). Nutrient composition of diets was planned using Food Works Professional Edition V7 (Xyris Software, 2012) and re-confirmed analytically using standard AOAC methods as 32%E, 17%E and 44%E from fat, protein and carbohydrate, respectively for all diets. While the diets contained biscuits and cake, the remainder of the diet was made up of healthy foods (fruits, vegetables, wholegrain bread and cereals, low fat dairy products) in order to ensure overall nutritional adequacy (See Supplementary Table 1 for selected daily nutrient intakes from a 8500 kJ diet). In addition, the 2-week run-in period was included to minimise any potential impact that transitioning from habitual diets to intervention diets may have caused.

Meals were prepared in commercial food manufacturing facilities (Community Chef, Victoria, Australia and Kyttons Bakery, SA, Australia) according to recipes developed by research dietitian.

Prescribed diets were eucaloric to maintain body weight. Participant’s individual energy requirements were determined using Schofield equation [20]. Diets were designed at 1000 kJ increments and participants assigned the closest 1000 kJ bracket. Remainder of the diet was made up of commercial breakfast cereal (provided), consumed with low fat milk and daily ‘low-fat snacks’ including fruit, low-fat dairy, bread and cereal options (not provided). Snacks could occasionally be swapped for low-fat discretionary product/s from a prescribed list which included alcoholic beverages for flexibility. Participants were requested to consume all foods provided and avoid foods outside of those prescribed.

Compliance to study treatments was monitored by intake checklists and weekly online surveys (Survey Gizmo, Widgix Software, LLC) and cross-monitored by dietitian at each visit. Percentage compliance scores were calculated for each intervention period using data on daily consumption of test fat food items (frozen meals, biscuits and cake) by totalling the reported intake of test fat and dividing it by the prescribed test fat intake for each individual based on their energy level. Subsequently, a mean value was derived for each intervention period. Participants also recorded their body weight (at home); 3 × /week during run-in and 1 × /week during intervention. If trends were observed in body weight changes (± ~1 kg during run-in; ± ~3 kg during intervention) or deviation from study protocol, adjustments were made to the prescribed energy intake as required.

### Lipid analysis

Plasma and serum were prepared by centrifugation at 4 °C (2100 g, 10 min; 2850 g, 15 min, respectively). Samples were stored at −80 °C until analysis at completion of intervention. Serum TC, TAG, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and non-esterified fatty acids (NEFA) were analysed using enzymatic kits (Beckman Coulter Inc, CA, USA; Randox Laboratories Ltd, County Antrim, UK) on a Beckman AU480 analyser. Intra-assay coefficient of variations (CVs) were TC: 0.78%; TAG: 0.86%; HDL-C: 0.69%; LDL-C: 1.79%; and NEFA: 1.61%. Serum Lp(a), ApoA1 and ApoB were measured using immunoturbidimetric kits purchased from above-listed suppliers. Intra-assay CVs Lp(a): 0.86%; ApoA1: 0.86%; ApoB: 0.92%.
Plasma fatty acids analysed by gas chromatography–mass spectrometry (GCMS) technique [21, 22], stereo-specific analysis of the test fats with nuclear magnetic resonance (NMR) spectroscopy [22] and LDL sub-fractions using Lipoprint testing system (Quantimetrix, USA).

**Statistical analysis**

Statistical power for this study is based on a priori hypothesis of not detecting a clinically meaningful difference in the primary outcome of TC:HDL-C ratio. A retrospective power calculation indicated that a sample size of 38 (number of completers in the current study) provided sufficient power (80%, two-tailed α = 0.05) to detect a minimum difference of 0.15 mmol/L in TC:HDL-C ratio using standard deviation (SD) difference of 0.32 (calculated from the current sample). A difference of 0.15 mmol/L is associated with <5% lower ischemic heart disease mortality [23].

Analysis was performed using SPSS software version 23 (IBM Corporation, New York, USA). Outcome variables were examined for normality using Kolmogorov–Smirnov, Shapiro–Wilk tests and normality plots. Non-normally distributed data were transformed into approximate normal distributions by logarithmic transformations (Lp(a), NEFA).

Primary analyses to compare outcome variables within and between test diets were performed using mixed effects longitudinal models. Because of large attrition rates (34%), analyses were performed on completers (n = 38) using unstructured repeated covariance matrix structure. Treatment and time were included as fixed factors and analysed for main effects and treatment*time interactions. All analyses were controlled for weight changes. Baseline levels were controlled for when contributing significantly to model. Data were examined for interaction effects due to order in which treatments were consumed by including allocation order as fixed factor in the model and investigating its interaction with treatment*time. This was removed when no allocation order interactions were evident. When significant treatment*time interactions were seen, post-hoc analysis was performed using repeated measures general linear model with Bonferroni adjustments. Results are presented as estimated marginal means (95% CI). Assumption of normally distributed residuals were met. P-values of <0.05 were considered significant.

**Results**

**Participants, diet and compliance**

Fifty-eight (58) participants commenced the run-in diet; 38 completed all treatments (Fig. 1). Three participants withdrew during the run-in phase and a further 17 after commencement of intervention. Reasons for withdrawal included dislike of dietary protocol, mostly due to intolerance to meals/snacks (n = 7) or restrictions the protocol imposed (n = 1), travel commitments (n = 7), personal reasons (n = 4) and following a serious adverse event (SAE), biliary colic (n = 1).

Mean compliance for completers were CB 97%, OO 99%, PO IV64 98% and palm olein IV72 (control) 99%. Dietary protocol deviations were small; 83 deviations (~2.3/ participant) recorded for the consumption of other high-fat foods over the 18 weeks.

Baseline characteristics (n = 55) (Table 2) reflect inclusion criteria; namely young healthy adults with anthropometric, blood pressure and serum lipid profiles within normal ranges. Baseline characteristics did not differ between completers and withdrawals (P > 0.05) except for serum TC that was slightly higher in withdrawals compared to completers (mean [SD], 4.79 [0.65] mmol/L versus 4.33 [0.83] mmol/L, P = 0.05).

Allocation order affected body weight and BMI (time*treatment*allocation order, P < 0.01) and is explained by a significant reduction in body weight and BMI during the 1st phase of the trial in the group who consumed OO first compared to CB and PO. No further changes were seen in weight or BMI during the trial with any of the dietary fats (Supplementary Table 2). Consequently, all statistical analyses were controlled for changes in body weight.

Changes in BP were not different between test diets (Supplementary Table 2).

Plasma PA (C16:0) levels decreased with the intake of OO versus PO. Plasma stearic acid (C18:0) increased with CB compared to PO. Plasma oleic acid (OA; C18:1) and total MUFA levels increased with OO compared to PO and CB (Table 3).

No differences were seen between any diets on serum lipids, including TC:HDL-C, TC, LDL-C, TAG, HDL-C, ApoA1, ApoB, Lp(a) or NEFA (Table 4). Significant allocation order interactions occurred for TC, LDL-C and ApoB, but the overall result of no difference between diets did not change. Those who consumed the diets in the order PO-OO-CB showed increases in LDL-C during the PO diet compared to those who received the diets in the order OO-CB-PO. A trend was seen for LDL-C to reduce during the OO diet compared to PO diet (P = 0.05) and for serum apolA1 to decrease with CB diet (P = 0.05).

LDL sub-fractions detected were mostly large particles, LDL-1 and LDL-2, with no LDL sub-fractions 4–7 detected (Table 5). No differences were seen between the different diets except for serum IDL-A which decreased with OO versus PO (estimated marginal mean (95%) differences in changes: −2.26 (−4.31, −0.21) mg/dL; −1.17 (−2.31, −0.03%), Bonferroni adjusted P < 0.05).
Including all participants, a total of 78 AEs (adverse events) were reported. None were associated with specific fat types. Most AEs were mild to moderate and related to respiratory infections, hence likely seasonal. Five AEs related to gastrointestinal/intolerance were considered possibly related to study diets including one SAE, biliary colic. One female participant was diagnosed with low iron status, possibly related to the study diets as she was on the lowest energy intake bracket providing less iron (12.8 mg/day) than the RDI (18 mg/day).

**Discussion**

The present study was designed to evaluate the assumption that the sn-2 position of dietary TAGs is a key determinant of plasma lipid outcomes of dietary fats and oils. As hypothesised, no differences were seen between test fats on the primary outcome, TC:HDL-C ratio, as well as a range of other lipid variables (TC, LDL-C, HDL-C, TAG, apoA1, apoB, apoA1:apoB, Lp(a), NEFA) and LDL sub-fractions.

Consistent with the current investigation, other studies in Australia and Malaysia using similar trial designs considering duration, amount of fat and study population, showed comparable non-hypercholesterolaemic effects between PO and OO [24–26]. A study in Danish men reported neutral effects of OO and PO on the TC:HDL-C ratio, but the OO diet resulted in a small (4.5%) significant decrease in plasma TC and LDL-C levels compared to the PO diet [14]. A recent meta-analysis also showed no effect
Table 3 Changes in selected plasma fatty acid levels (% of total fatty acids) from baseline and comparisons between treatments (n = 38)

| Variable          | Time (wk) | CB          | OO          | PO          | P-valuesa |
|-------------------|----------|-------------|-------------|-------------|-----------|
| Myristic acid (C14:0) | 0        | 0.61 (0.52, 0.71) | 0.53 (0.46, 0.60) | 0.52 (0.46, 0.57) | –         |
|                   | Δ4       | −0.04 (−0.12, 0.05) | 0.01 (−0.08, 0.11) | 0.06 (−0.001, 0.13) | 0.28      |
| Palmitic acid (C16:0) | 0        | 25.6 (24.2, 27.0) | 27.6 (25.8, 29.4) | 25.6 (24.4, 26.9) | –         |
|                   | Δ4       | −1.96 (−3.77, −0.15)b | −3.53 (−5.92, −1.15)b,c | 0.65 (−1.02, 2.32) | 0.01      |
| Saturated acid (C18:0) | 0        | 8.79 (8.04, 9.55) | 9.20 (8.27, 10.1) | 9.28 (8.62, 9.93) | –         |
|                   | Δ4       | 1.35 (0.32, 2.39)b,d | −0.78 (−1.90, 0.33) | −0.48 (−1.13, 0.18) | 0.01      |
| Oleic acid (C18:1n-9cis) | 0        | 18.0 (16.2, 19.7) | 15.9 (13.7, 18.1) | 17.2 (15.5, 18.9) | –         |
|                   | Δ4       | 2.44 (0.41, 4.48)b | 5.10 (2.90, 7.30)b,c | 0.63 (−0.68, 1.95) | 0.002     |
| Linoleic acid (C18:2n-6cis) | 0        | 24.7 (23.1, 26.2) | 23.2 (20.9, 25.6) | 25.0 (23.6, 26.5) | –         |
|                   | Δ4       | −0.73 (−2.82, 1.35) | 0.25 (−2.35, 2.84) | −0.09 (−1.90, 1.72) | 0.80      |
| Arachidonic acid (C20:4n-6) | 0        | 5.39 (4.37, 6.42) | 4.82 (3.78, 5.85) | 5.59 (4.63, 6.56) | –         |
|                   | Δ4       | 0.77 (−0.08, 1.61) | 1.08 (0.30, 1.87) | 0.19 (−0.47, 0.84) | 0.18      |
| Total SFA         | 0        | 36.5 (32.6, 40.5) | 37.1 (31.3, 42.9) | 37.8 (35.6, 39.9) | –         |
|                   | Δ4       | −1.30 (−4.21, 1.62) | −0.06 (−5.77, 5.65) | −1.28 (−3.42, 0.85) | 0.94      |
| Total MUFA        | 0        | 25.3 (24.1, 26.4) | 24.6 (23.4, 25.7) | 24.4 (23.4, 25.4) | –         |
|                   | Δ4       | 0.79 (−0.49, 2.08) | 4.05 (2.57, 5.53)b,c | 0.18 (−0.67, 1.03) | <0.001    |
| Total PUFA        | 0        | 36.7 (35.1, 38.2) | 34.7 (32.5, 36.9) | 36.8 (35.3, 38.3) | –         |
|                   | Δ4       | −0.51 (−2.87, 1.86) | 0.33 (−2.12, 2.78) | −0.84 (−2.80, 1.12) | 0.79      |

CB cocoa butter, MUFA monounsaturated fatty acids, OO olive oil, PO palm olein, PUFA polyunsaturated fatty acids, SFA saturated fatty acids, Δ estimated marginal mean (95%CI)

a,b,cComparisons within and between treatment groups were performed using mixed effects longitudinal models

bChange significantly different from baseline (P < 0.05)

c,d,ePost-hoc comparisons between treatments significantly different (P < 0.05) (c, OO vs. PO; d, CB vs. PO; e, OO vs. CB); analysis performed using Repeated measures General Linear Model with Bonferroni adjustments for multiple comparisons

of PO compared to MUFA-rich fats (6 studies) or PO compared to stearic acid (3 studies) on TC:HDL-C ratio [27]. Although a trend was seen for more favourable changes in serum LDL-C after the OO diet compared to the PO diet, the mean differences in LDL-C were relatively small (0.12 mmol/L); associated with an estimated coronary heart disease (CHD) mortality risk reduction of only ~3% [28].

Only a few dietary trials used CB sources [29, 30] while several used shea butter as the source of stearic acid [31–33], the main fatty acid in CB, generally demonstrating cholesterol-neutral properties. Shea butter has a similar stereospecificity compared to CB with most SFA in sn−1,3 position [32], but are lower in PA (4% versus 26%) and higher in oleic acid (OA) (49% versus 33%) and linoleic acid (7% versus 2.5%) compared to CB [34]. The non-hypercholesterolaemic effects of stearic acid may be explained by enhanced faecal excretion [31] due to its stereospecificity [35] and by rapid conversion of stearic acid to OA [33, 36]. In support of the latter, the current study showed a significant increase from baseline to end in plasma OA with the CB diet.

Assessment of LDL particle size provides additional information regarding the atherogenic potential of dietary interventions. Participants in the current study had mostly large, buoyant, less atherogenic [37, 38] LDL particles (serum LDL-1 and -2 sub-fractions) and although the diets did not differ with regard to their effects on LDL sub-fractions; it is important to note that none of the diets induced lipoprotein sub-fraction population/profiles deemed more atherogenic. The only notable change in lipoprotein sub-fractions occurred following the OO diet where reduced levels of serum IDL-A compared to PO was observed. IDL-A’s are triglyceride-rich particles as they originate from the catabolism of very low-density lipoprotein (VLDL) by lipoprotein lipase [39]. Increased IDL have been reported to promote the progression of atherosclerosis [40, 41]. Whilst a difference was registered in IDL-A between the OO and PO diets, this change was due to a decrease in response to the OO diet while no change was observed after the PO diet. The exact origin of this lipoprotein sub-fraction is not clearly evident from the present findings as none of the major lipid parameters (LDL-C, HDL-C and triglycerides) were perturbed by any of the diets.

Although the current study hypothesis was based on plasma lipid outcomes in response to the type of fatty acid (s) esterified to the sn-2 position of TAGs, the present
Table 4 Changes from baseline in serum lipid profiles and comparisons between treatments (n = 38)

| Variable          | Time (wk) | CB       | OO       | PO       | P-values
|-------------------|-----------|----------|----------|----------|-----------
| TC (mmol/L)       | 0         | 4.48 (4.22, 4.75) | 4.40 (4.14, 4.66) | 4.48 (4.21, 4.73) | –         |
|                   | Δ4        | −0.05 (−0.18, 0.08) | −0.04 (−0.20, 0.11) | 0.06 (−0.04, 0.16) | 0.14      |
| LDL-C (mmol/L)    | 0         | 2.78 (2.60, 2.97) | 2.73 (2.53, 2.93) | 2.79 (2.59, 2.99) | –         |
|                   | Δ4        | 0.00 (−0.12, 0.12) | −0.05 (−0.17, 0.08) | 0.07 (−0.01, 0.14) | 0.05      |
| HDL-C (mmol/L)    | 0         | 1.47 (1.35, 1.59) | 1.44 (1.33, 1.55) | 1.46 (1.36, 1.56) | –         |
|                   | Δ4        | −0.05 (−0.11, 0.0) | 0.00 (−0.04, 0.04) | −0.01 (−0.04, 0.02) | 0.31      |
| TC/HDL-C (mmol/L) | 0         | 3.15 (2.95, 3.35) | 3.14 (2.92, 3.37) | 3.14 (2.93, 3.36) | –         |
|                   | Δ4        | 0.06 (−0.05, 0.16) | −0.01 (−0.15, 0.13) | 0.08 (0.00, 0.15) | 0.53      |
| TAG (mmol/L)      | 0         | 0.91 (0.80, 1.03) | 0.85 (0.75, 0.96) | 0.82 (0.73, 0.92) | –         |
|                   | Δ4        | −0.07 (−0.15, 0.01) | 0.01 (−0.09, 0.10) | 0.03 (−0.03, 0.08) | 0.07      |
| ApoA1 (g/L)       | 0         | 1.49 (1.40, 1.59) | 1.46 (1.37, 1.55) | 1.47 (1.39, 1.55) | –         |
|                   | Δ4        | −0.07 (−0.11, −0.02)b | 0.01 (−0.02, 0.05) | 0.00 (−0.03, 0.04) | 0.05      |
| ApoB (g/L)        | 0         | 0.79 (0.74, 0.83) | 0.79 (0.73, 0.84) | 0.79 (0.74, 0.85) | –         |
|                   | Δ4        | 0.00 (−0.02, 0.03) | −0.02 (−0.05, 0.02) | 0.01 (−0.01, 0.03) | 0.18      |
| ApoA1:ApoB        | 0         | 1.95 (1.80, 2.09) | 1.91 (1.78, 2.04) | 1.91 (1.77, 2.05) | –         |
|                   | Δ4        | −0.09 (−0.18, −0.01)b | 0.03 (−0.05, 0.10) | −0.03 (−0.07, 0.02) | 0.13      |
| Lp(a) (nmol/L)    | 0         | 33.7 (20.7, 46.7) | 36.4 (21.8, 51.1) | 32.6 (20.4, 44.9) | –         |
|                   | Δ4        | 1.85 (−1.42, 5.12) | 0.34 (−1.66, 2.34) | 1.96 (−1.94, 5.86) | 0.42      |
| NEFA (mmol/L)     | 0         | 0.39 (0.29, 0.50) | 0.36 (0.28, 0.44) | 0.42 (0.31, 0.54) | –         |
|                   | Δ4        | −0.06 (−0.17, 0.06) | 0.21 (−0.06, 0.10) | −0.02 (−0.12, 0.08) | 0.79      |

All values are estimated marginal means (95% CI)

HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), NEFA non-esterified fatty acids, TAG triacylglycerol, TC total cholesterol

a,bComparisons within and between treatment groups were performed using mixed effects longitudinal models. All analyses were controlled for weight changes during the study. Models for TC, LDL-C and ApoB in addition included the following variables that significantly contributed to the model: time*treatment*allocation order and baseline levels

bChange significantly different from baseline (P < 0.05)

Analyses were performed on log transformed data

ApoA1 (g/L) 0 1.49 (1.40, 1.59) 1.46 (1.37, 1.55) 1.47 (1.39, 1.55) –

Δ4 −0.07 (−0.11, −0.02)b 0.01 (−0.02, 0.05) 0.00 (−0.03, 0.04) 0.05

Δ4 −0.09 (−0.18, −0.01)b 0.03 (−0.05, 0.10) −0.03 (−0.07, 0.02) 0.13

Δ4 1.85 (−1.42, 5.12) 0.34 (−1.66, 2.34) 1.96 (−1.94, 5.86) 0.42

Δ4 0.39 (0.29, 0.50) 0.36 (0.28, 0.44) 0.42 (0.31, 0.54) –

Δ4 −0.06 (−0.17, 0.06) 0.21 (−0.06, 0.10) −0.02 (−0.12, 0.08) 0.79

A better approach would have been to directly compare the same fat source with fatty acids distribution in the sn-2 position versus sn-1,3 positions, for example, structured TAGs where PA is esterified to sn-2 position (sn-2 palmitate). Hence, the non-hypercholesterolaemic effects of the two test fats rich in SFA compared to OO could have been due to a combination of reasons including the sn-2 position itself, the presence of relatively high proportion of OA (>30% in CB and ~45% PO), presence of tocotrienols and plant sterols in PO [42] or the rapid conversion of stearic acid to OA in the case of CB [33, 36].

A strength of the current study is the inclusion of a range of traditional and new emerging lipid markers of CVD risk. Most previous studies focused on TC and LDL-C, providing limited view of the atherogenic potential of a given fat type. The primary outcome, TC:HDL-C ratio, provides a better overall indication of CHD risk and has been shown to be a stronger predictor of ischaemic heart disease mortality than TC alone. Serum apoB is considered an important emerging CVD risk stratification marker and has been shown to perform better than LDL-C in CVD risk prediction [43]. Recent results from the prospective PURE study, involving 18 countries, n = 125,287, suggested apoB/apoA1 ratio was the best overall indicator of the effect of SFA on CVD risk [44]. Results from the current study consistently showed no difference between dietary fat types on any of these lipid markers, increasing overall confidence in the findings.

Other strengths include rigorous dietary intake control; a highly controlled feeding protocol, where the test fats were delivered in meals and snacks to participants for the duration of the study 7 days a week. Reported compliance was high (98%+) which was confirmed by changes in plasma fatty acids that mirrored composition of the source fats. The high intake of test fats (20%E, two-thirds of total fat intake) ensured that if an effect was present it would have been apparent. PO and CB are not common in the typical Australian diet and are most likely only consumed through commercial food products like bakery and fried products, hence intakes of these fat types are typically much lower.
than the amounts consumed in this study. Furthermore, the study had sufficient statistical power to detect clinical meaningful differences in the primary outcome variable and most lipid variables.

The allocation order interactions seen for TC, LDL-C and ApoB is a limitation. Those who consumed the diets in the order PO-OO-CB showed significant increases in LDL-C during the PO diet compared to those who received the diets in the order OO-CB-PO. This may have been instigated by a slightly lower LDL-C levels at baseline in the PO-OO-CB group (2.66 [2.30, 3.02] mmol/L) compared to the OO-CB-PO group (2.84 [2.54, 3.15] mmol/L). The reduction in body weight and BMI in the group consuming OO in the first phase of the trial may have further aggrated this effect, although weight changes were controlled for in the statistical analysis. Despite these allocation order interactions, the overall result of no difference between diets did not change.

Other potential limitations of the study include that results can only be generalised to healthy young adults; hence it is unclear how these fat types may affect obese, hypercholesterolaemic individuals, children or older adults.

Table 5 Changes from baseline in serum lipoprotein sub-fractions and comparisons between treatments (n = 38)

| Variable     | Time (wk) | CB             | OO             | PO             | P-values<sup>a</sup> |
|--------------|-----------|----------------|----------------|----------------|---------------------|
| VLDL (mg/dL) | 0         | 23.1 (21.1, 25.1) | 21.5 (20.0, 23.1) | 21.6 (19.8, 23.5) | –                   |
| Δ4           |           | −1.17 (−2.91, 0.58) | 0.12 (−1.31, 1.54) | 0.05 (−1.08, 1.18) | 0.46                |
| LDL-C (mg/dL)| 0         | 18.5 (17.0, 20.1) | 17.6 (15.9, 19.4) | 18.8 (17.4, 20.3) | –                   |
| Δ4           |           | −0.87 (−1.74, 0.00) | −0.85 (−2.30, 0.60) | −0.13 (−1.2, 0.93) | 0.52                |
| LDL-B (mg/dL)| 0         | 9.12 (8.32, 9.93) | 10.0 (7.76, 12.3) | 9.27 (8.17, 10.4) | –                   |
| Δ4           |           | −0.07 (−0.71, 0.57) | −1.35 (−3.29, 0.58) | 1.27 (−0.83, 3.38) | 0.17                |
| IDL-A (mg/dL)| 0         | 18.1 (15.9, 20.4) | 18.3 (15.9, 20.7) | 18.3 (15.8, 20.8) | –                   |
| Δ4           |           | 0.55 (−0.92, 2.01) | −1.80 (−3.41, −0.18)<sup>b,c</sup> | 0.47 (−0.73, 1.66) | 0.03                |
| LDL-1 (mg/dL)| 0         | 35.0 (31.8, 38.2) | 34.0 (30.8, 37.2) | 34.8 (32.1, 37.5) | –                   |
| Δ4           |           | 1.67 (−0.18, 3.52) | −0.07 (−2.62, 2.47) | 0.59 (−1.58, 2.76) | 0.5                 |
| LDL-2 (mg/dL)| 0         | 11.4 (8.57, 14.2) | 11.3 (8.13, 14.5) | 11.3 (8.05, 14.5) | –                   |
| Δ4           |           | 0.28 (−1.07, 1.64) | 1.52 (−0.58, 3.62) | 0.19 (−1.43, 1.80) | 0.41                |
| LDL-3 (mg/dL)| 0         | 0.50 (0.15, 0.85) | 0.72 (−0.05, 1.50) | 0.74 (0.02, 1.46) | –                   |
| Δ4           |           | −0.07 (−0.40, 0.27) | 0.04 (−0.80, 0.87) | −0.38 (−1.00, 0.22) | 0.09                |
| VLDL (%)     | 0         | 13.4 (12.4, 14.4) | 12.9 (12.1, 13.7) | 12.6 (11.7, 13.5) | –                   |
| Δ4           |           | −0.50 (−1.27, 0.26) | 0.23 (−0.41, 0.86) | −0.11 (−0.68, 0.46) | 0.38                |
| IDL-C (%)    | 0         | 10.7 (10.1, 11.3) | 10.5 (9.64, 11.3) | 11.0 (10.4, 11.6) | –                   |
| Δ4           |           | −0.43 (−0.82, −0.04) | −0.31 (−0.89, 0.26) | −0.26 (−0.86, 0.34) | 0.88                |
| IDL-B (%)    | 0         | 5.25 (4.86, 5.64) | 5.95 (4.73, 7.17) | 5.29 (4.89, 5.69) | –                   |
| Δ4           |           | −0.03 (−0.39, 0.33) | −0.73 (−1.80, 0.34) | 0.81 (−0.42, 2.03) | 0.17                |
| IDL-A (%)    | 0         | 10.5 (9.32, 11.7) | 11.0 (9.69, 12.3) | 10.6 (9.30, 11.9) | –                   |
| Δ4           |           | 0.44 (−0.32, 1.19) | −1.00 (−1.89, −0.12)<sup>b,c</sup> | 0.23 (−0.41, 0.87) | 0.03                |
| LDL-1 (%)    | 0         | 20.1 (19.2, 21.0) | 19.7 (18.3, 21.1) | 20.1 (19.0, 21.2) | –                   |
| Δ4           |           | 1.01 (0.11, 1.92)<sup>b</sup> | 0.52 (−0.94, 1.98) | 0.07 (−1.16, 1.29) | 0.45                |
| LDL-2 (%)    | 0         | 6.47 (4.96, 7.97) | 6.37 (4.82, 7.92) | 6.34 (4.73, 7.94) | –                   |
| Δ4           |           | 0.14 (−0.59, 0.87) | 1.17 (0.12, 2.22)<sup>b</sup> | 0.07 (−0.71, 0.85) | 0.13                |
| LDL-3 (%)    | 0         | 0.27 (0.09, 0.45) | 0.37 (0.05, 0.70) | 0.39 (0.08, 0.70) | –                   |
| Δ4           |           | −0.03 (−0.20, 0.14) | 0.07 (−0.29, 0.43) | −0.19 (−0.43, 0.05) | 0.09                |

All values are estimated marginal means (95%CI)

<sup>a</sup>Comparisons within and between treatment groups were performed using mixed effects longitudinal models. All analyses were controlled for weight changes during the study. Models for IDL-C%, IDL-C mg/dL, IDA-A mg/dL and LDL-1 mg/dL also included time*treatment*allocation order

<sup>b</sup>Change significantly different from baseline (P<0.05)

<sup>c</sup>Post-hoc comparisons between OO vs. PO treatments significantly different (P<0.05); analysis performed using Repeated measures General Linear Model with Bonferroni adjustments for multiple comparisons
In conclusion, consistent with the hypothesis, PO and CB both rich in SFA, but containing primarily unsaturated fatty acid in the sn-2 position of TAG, did not differ from OO with regard to their effects on lipid profiles.

Acknowledgements The authors would like to thank participants of the study for their perseverance and compliance. We also thank Dr. Campbell Thompson (Adelaide University) for medical oversight and the CSIRO clinical team including Jessica Southwood (Lead Clinical Trials Coordinator); Julia Weaver (Clinical Trials Coordinator); Anne McGuffin (Clinical Trials Coordinator); Vanessa Courage (Clinical Research Technician); Lindy Lawson (Research Nurse); Heather Webb (Research Nurse); Theresa McKinnon (Research Nurse); Auri-anne Webber (Research Nurse); Kirsten Keys (Research Nurse); Gemma Williams (Research Dietitian); Megan Rebuli (Research Dietitian); Brooke Wymond (Research Dietitian); Bradley Klingner (Clinical Research Technician); Leonie Underwood (Clinical Research Technician); Cathryn Pape (Laboratory Technician); Michael Adams (Laboratory Technician); Julie Dellimore (Laboratory Technician); Bruce May (Laboratory Technician); Paul Orchard (Laboratory Technician); and Julie Syrette (Data Management). We would also like to thank Dr Phooi Tee Voon and Dr Lee Sin Tien from the Malaysian Palm Oil Board for analysis of test fatty acid composition and stereo-specific distribution as well as serum lipoprotein sub-fraction analysis.

Funding Malaysian Palm Oil Board (Kuala Lumpur, Malaysia) provided funding for the study. The funding sources had no influence over the conduct of the research, analysis, reporting and interpretation of the data

Author contributions WS, BBE. GJM. MA: Designed the work that led to the submission, acquired data, and played an important role in interpreting the results; contributed to the drafting and revision of manuscript; approved the final version; agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. WS: Has had full access to the data in the study and final responsibility for the decision to submit for publication.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. World Health Organisation. Cardiovascular Disease. World Heart Day 2017. 2017 [Available from: http://www.who.int/heartdisease/en/]
2. Food and Agriculture Organisation of the United Nations. Fats and fatty acids in human nutrition. Report of an expert consultation. Rome, Italy, 2010.
3. Briggs MA, Petersen KS, Kris-Etherton PM. Saturated Fatty Acids and Cardiovascular Disease: Replacements for Saturated Fat to Reduce Cardiovascular Risk. Healthcare. 2017:5: pii: E29.
4. Food and Drug Administration. Final determination regarding partially hydrogenated oils. FDA–2013–N–1317. Fed Regist. 2016;80:34650–70.
5. Kritchevsky D. Overview: dietary fat and atherosclerosis. Asia Pac J Clin Nutr. 2000;9:141–5.
6. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146–55.
7. Michra R, Mozaffarian D. Saturated fat and cardiometabolic risk factors, coronary heart disease, stroke, and diabetes: a fresh look at the evidence. Lipids. 2010;45:893–905.
8. Brink EJ, Haddeman E, de Fouw NJ, Weststrate JA. Positional distribution of stearic acid and oleic acid in a triacylglycerol and dietary calcium concentration determines the apparent absorption of these fatty acids in rats. J Nutr. 1995;125:2379–87.
9. Mattson FH, Nolen GA, Webb MR. The absorbability by rats of various triglycerides of stearic and oleic acid and the effect of dietary calcium and magnesium. J Nutr. 1979;109:1682–7.
10. Zock PL, Devries JHM, Defouw NJ, Katan MB. Positional distribution of fatty acids in dietary triglycerides: effects on fasting blood lipoprotein concentrations in humans. Am J Clin Nutr. 1995;61:48–55.
11. Hunter JE. Studies on effects of dietary fatty acids as related to their position on triglycerides. Lipids. 2001;36:655–68.
12. Lien EL. The role of fatty acid composition and positional distribution in fat absorption in infants. J Pediatr. 1994;125(5 Pt 2):S62–8.
13. Zhang J, Ping W, Chunrong W, Shou CX, Keyou G. Non-hypercholesterolemic effects of a palm oil diet in Chinese adults. J Nutr. 1997;127:509S–13S.
14. Tholstrup T, Hjersted J, Raff M. Palm olein increases plasma cholesterol moderately compared with olive oil in healthy individuals. Am J Clin Nutr. 2011;94:1426–32.
15. Forsythe CE, French MA, Goh YK, Claudinin MT. Cholesterolaemic influence of palmitic acid in the sn-1, 3 v. the sn-2 position with high or low dietary linoleic acid in healthy young men. Br J Nutr. 2007;98:337–44.
16. Filippou A, Teng KT, Berry SE, Sanders TA. Palmitic acid in the sn-2 position of dietary triacylglycerols does not affect insulin secretion or glucose homeostasis in healthy men and women. Eur J Clin Nutr. 2014;68:1036–41.
17. Nestel PJ, Noakes M, Belling GB, McArthur R, Clifton PM. Effect on plasma lipids on interesterifying a mix of edible oils. Am J Clin Nutr. 1995;62:950–5.
18. Alfieri A, Imperini E, Nigro E, Vitucci D, Ornu S, Daniele A, et al. Effects of plant oil interesterified triacylglycerols on lipemia and human health. Int J Mol Sci. 2017;19: pii: E104.
19. Tsartsou E, Proutsos N, Castanas E, Kampa M. Network meta-analysis of metabolic effects of olive-oil in humans shows the importance of olive oil consumption with moderate polyphenol levels as part of the Mediterranean diet. Front Nutr. 2019;6:6.
20. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr. 1985;39(Suppl 1):5–41.

21. Hendrie GA, Golley RK. Changing from regular-fat to low-fat dairy foods reduces saturated fat intake but not energy intake in 4-13-y-old children. Am J Clin Nutr. 2011;93:1117–27.

22. Teh SS, Voon PT, Ng YT, Ong SH, Ong ASH, Choo YM. Effects of fatty acids at different positions in the triglycerides on cholesterol levels. J Oil Palm Res. 2016;28:211–21.

23. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (Lond, Engl). 2007;370:1829–39.

24. Choudhury N, Tan L, Truswell AS. Comparison of palmolein and olive oil: effects on plasma lipids and vitamin E in young adults. Am J Clin Nutr. 1995;61:1043–51.

25. Ng TK, Hayes KC, DeWitt GF, Jegathesan M, Satgunasingam N, Choudhury N, Tan L, Truswell AS. Comparison of palmolein and olive oil: effects on plasma lipids and vitamin E in young adults. Am J Clin Nutr. 1995;61:1043–51.

26. Voon PT, Ng TK, Lee VK, Nesaretnam K. Diets high in palmitic acid (16:0), lauric and myristic acids (12:0 + 14:0), or oleic acid (18:1) do not alter postprandial or fasting plasma homocysteine and inflammatory markers in healthy Malaysian adults. Am J Clin Nutr. 2011;94:1451–7.

27. Fattore E, Bosetti C, Briglioni F, Agostoni C, Fattore G. Palm oil and blood lipid-related markers of cardiovascular disease: a systematic review and meta-analysis of dietary intervention trials. Am J Clin Nutr. 2014;99:1331–46.

28. Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 2007;29:778–94.

29. Kelly FD, Sinclair AJ, Mann NJ, Turner AH, Raffin FL, Blandford MV, et al. Short-term diets enriched in stearic or palmitic acids do not alter plasma lipids, platelet aggregation or platelet activation status. Eur J Clin Nutr. 2002;56:490–9.

30. Kris-Etherton PM, Derr J, Mitchell DC, Mustad VA, Russell ME, McDonnell ET, et al. The role of fatty acid saturation on plasma lipids, lipoproteins, and apolipoproteins: I. Effects of whole food diets high in cocoa butter, olive oil, soybean oil, dairy butter, and milk chocolate on the plasma lipids of young men. Metab: Clin Exp. 1993;42:121–9.

31. Dougherty RM, Aliman MA, Iacono JM. Effects of diets containing high or low amounts of stearic-acid on plasma-lipoprotein fractions and fecal fatty-acid extretion of men. Am J Clin Nutr. 1995;61:1120–8.

32. Storm H, Thomsen C, Pedersen E, Rasmussen O, Christiansen C, Hermansen K. Comparison of a carbohydrate-rich diet and diets rich in stearic of palmitic acid in NIDDM patients - Effects on lipids, glycemic control, and diurnal blood pressure. Diabetes care. 1997;20:1807–13.

33. Tholstrup T, Markmann P, Jespersen J, Sandstrom B. Fat high in stearic-acid favorably affects blood-lipids and factor-VII coagulation activity in comparison with fats high in palmitic acid or high in myristic and lauric acids. Am J Clin Nutr. 1994;59:371–7.

34. Honfo FG, Akissoe N, Linnemann AR, Soumanou M, Van Boekel MA. Nutritional composition of shea products and chemical properties of shea butter: a review. Crit Rev Food Sci Nutr. 2014;54:673–86.

35. Nestel PJ, Pomeroy S, Kay S, Sasahara T, Yamashita T. Effect of a stearic acid-rich, structured triacylglycerol on plasma lipid concentrations. Am J Clin Nutr. 1998;68:1196–201.

36. Bonanome A, Grundy SM. Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. New Engl J Med. 1988;318:1244–8.

37. Hirayama S, Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012;414:215–24.

38. Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract. 2007;61:1949–56.

39. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141:358–67.

40. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022–6.

41. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762–70.

42. Fattore E, Fanelli R. Palm oil and palmitic acid: a review on cardiovascular effects and carcinogenicity. Int J food Sci Nutr. 2013;64:648–59.

43. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011;58:457–63.

44. Mente A, Dehghan M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, et al. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. lancet Diabetes Endocrinol. 2017;5:774–87.